drugset / Trial / NCT05515627
Atezolizumab for Idiopathic Pulmonary Fibrosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).
Timeline
- Start
- 2023-02-15
- Primary completion
- 2026-06-30
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |